CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CD19+22 CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD19+22 CAR-T overview

Gene therapy is under development for the treatment of R/R B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, mucosa-associated lymphoid tissue or malt-lymphoma, burkitt lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, diffuse large b-Cell lymphoma, relapsed and refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. It is a chimeric antigen receptor modified-T cell (CART). The therapeutic candidate acts by targeting cells expressing CD19 and CD22. It is administered through parenteral route.

Hebei Senlang Biotechnology overview

Hebei Senlang Biotechnology is a pharamaceutial and healthcare company which is involved in using bio technology for treatment of immune cells. The company is headquartered in Dongguan, Hebei, China.

For a complete picture of CD19+22 CAR-T’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.